The global Biliary Atresia Treatment Market is estimated to be valued at US$ 1,064.2 Mn or Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2027 to 2030, as highlighted in a new report published by Coherent Market Insights.
Biliary atresia is a rare pediatric disease that causes inflammation and fibrosis of the biliary ducts outside and inside the liver. This leads to a condition called cholestasis where bile cannot drain from the liver causing jaundice in infants. If left untreated, it can progress to cirrhosis and liver failure. The current treatment involves surgical removal of damaged bile ducts (Kasai portoenterostomy) along with bile flow restoration medications and liver transplantation. With advancements in genetics, stem cells and tissue engineering, new treatment avenues are opening to cure biliary atresia at early stages.
Market key trends:
Automation and AI are transforming drug discovery by speeding up the process and improving clinical outcomes. Companies are leveraging machine learning algorithms to identify potential drug candidates and streamline preclinical testing. For example, Anthropic developed Constitutional AI, an AI assistant trained via self-supervision to be helpful, harmless, and honest for accelerating drug discovery research. Development of organs-on-chips and microphysiological systems mimicking liver conditions will enable preclinical testing of novel drug formulations in human-relevant models before clinical trials. This reduces costs and risks associated with drug development.
Threat of new entrants: Low. Significant capital requirements and economies of scale pose barriers for new companies to enter the market.
Bargaining power of buyers: Moderate. The availability of alternative treatment options provides buyers with some negotiation power regarding pricing.
Bargaining power of suppliers: Low. The market has a concentration of large pharmaceutical companies that supply disease-specific drugs.
Threat of new substitutes: Low. There exist limited alternative treatment options for biliary atresia with similar efficacy.
Competitive rivalry: High. Major players compete on the basis of drug pipeline, portfolio expansion, and pricing.
The global biliary atresia treatment market is expected to witness high growth, exhibiting a CAGR of 8.1% over the forecast period, due to increasing research investments and new drug approvals.
The market size for 2023 is estimated to be US$ 1,064.2 Mn. North America currently dominates the market due to high healthcare expenditure and presence of major market players in the region. However, Asia Pacific is anticipated to be the fastest growing market owing to rising healthcare infrastructure and growing medical tourism in countries like India and China.
Key players operating in the biliary atresia treatment market are AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals. Major players are focusing on expanding their product portfolios through acquisitions and partnerships to strengthen their market position.